Trial · NCT01503775
TRUfill®'s Line in Intracranial aNeurysm Embolisation
NCT01503775, Completed, Codman & Shurtleff
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. TRUfill®'s Line in Intracranial aNeurysm Embolisation. Trials, record NCT01503775. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01503775
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- TRUfill®'s Line in Intracranial aNeurysm Embolisation
- NCT number
- NCT01503775
- Status
- Completed
- Enrollment
- 171 participants, actual
- Lead sponsor
- Codman & Shurtleff
- Conditions
- Aneurysms
- First posted
- 2012-01-04
- Last updated
- 2017-06-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The long term safety of the coiling procedure with the CODMAN TRUFILL®'s line of coils will be assessed by the combined morbidity-mortality rate (CMMR) observed during the procedure and up to 1 year post-procedure follow-up. | Observed during the procedure and up to 1 year post-procedure follow-up | |
| Secondary | The procedural CMMR observed during the procedure and up to 30 Days post procedure follow-up. | Observed during the procedure and up to 30 Days post procedure follow-up. | |
| Secondary | The rate of permanent morbidity and mortality observed at 30 Days and at 1 year post-procedure follow-up, defined as a mRS of 3 to 6. | Observed at 30 Days and at 1 year post-procedure follow-up | |
| Secondary | The rate of absence of deterioration or improvement of the neurological status observed at 30 days and at 1 year post procedure follow-up | Observed at 30 days and at 1 year post procedure follow-up | |
| Secondary | The overall rate of Adverse Event/Serious Adverse Event observed during the procedure, at 30 days and up to 1 year post-procedure follow-up | Observed during the procedure, at 30 days and up to 1 year post-procedure follow-up | |
| Secondary | The rate of Adverse Event/Serious Adverse Event related to the device and/or to the procedure observed during the procedure, at 30 days and up to 1 year post-procedure follow-up | Observed during the procedure, at 30 days and up to 1 year post-procedure follow-up | |
| Secondary | The rate of Unanticipated Adverse Device Effects observed during the procedure, at 30 days and up to 1 year post-procedure follow-up | Observed during the procedure, at 30 days and up to 1 year post-procedure follow-up | |
| Secondary | The rate of per-procedural subarachnoid hemorrhage of the treated aneurysm and rate of per-procedural SAH leading to a modification of the procedure initially planned | During the procedure | |
| Secondary | The rate of recurrent subarachnoid hemorrhage of the treated aneurysm at one-year post-procedure follow-up | 1 year post-procedure | |
| Secondary | The rate of aneurysm occlusion at the end of the procedure and at 1 year post-procedure follow-up | End of the procedure and at 1 year post-procedure follow-up |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01503775
GET https://conductscience.org/api/trials/v1/NCT01503775/registered